Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Knight Therapeutics Inc.
DescriptionSelective nNOS inhibitor and selective mu opioid agonist
Molecular Target Neuronal nitric oxide synthase 1 (NOS1) (nNOS) ; Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist; Nitric oxide (NO) synthase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationPain
Indication DetailsTreat severe pain
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today